• 1
    Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 2
    Kobayashi S, Inoue N, Ohashi Y et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003; 23: 1398404.
  • 3
    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 83643.
  • 4
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 155765.
  • 5
    Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 138797.
  • 6
    Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499511.
  • 7
    Akerblom HK, Viikari J, Uhari M et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children's and families’ state of health. Acta Paediatr Scand Suppl 1985; 318: 4963.
  • 8
    Juonala M, Viikari JS, Hutri-Kähönen N et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med 2004; 255: 45768.
  • 9
    Ainsworth BE, Haskell WL, Leon AS et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993; 25: 7180.
  • 10
    Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 7637.
  • 11
    Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003; 107: 4437.
  • 12
    Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148: S1926.
  • 13
    de Maat MP, Kluft C. Determinants of C-reactive protein concentration in blood. Ital Heart J 2001; 2: 18995.
  • 14
    Imhof A, Frohlich M, Loewel H et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003; 49: 66972.
  • 15
    Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 62136.
  • 16
    Yamada S, Gotoh T, Nakashima Y et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 118390.
  • 17
    Sampietro T, Bigazzi F, Dal Pino B et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation 2002; 105: 114.
  • 18
    Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 275867.
  • 19
    Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003; 73: 124552.
  • 20
    Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 2004; 28: 9981003.
  • 21
    Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 7136.
  • 22
    Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 2148.
  • 23
    Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004; 93: 123842.
  • 24
    Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004; 50: 57481.
  • 25
    Lowe GD. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med 2004; 256: 36174.
  • 26
    Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 27
    Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 178590.
  • 28
    Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am J Cardiol 2004; 93: 2215.
  • 29
    Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003; 11: 105564.
  • 30
    Godefroi R, Klementowicz P, Pepler C, Lewis B, McDonough K, Goldberg RJ. Levels of, and factors associated with, C-reactive protein in employees attending a company-sponsored cardiac screening program. Cardiology 2005; 103: 1804.
  • 31
    Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 8049.
  • 32
    Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 166873.
  • 33
    Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 21658.
  • 34
    Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 143941.
  • 35
    Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 20949.
  • 36
    Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 11947.
  • 37
    Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96102.
  • 38
    Blackburn R, Giral P, Bruckert E et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001; 21: 19628.
  • 39
    Jarvisalo MJ, Harmoinen A, Hakanen M et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002; 22: 13238.
  • 40
    Folsom AR, Pankow JS, Tracy RP et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 1127.
  • 41
    Juonala M, Viikari JS, Laitinen T et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: The Cardiovascular Risk in Young Finns Study. Circulation 2004; 110: 291823.